Instadose Competitors
| INSD Stock | USD 0.0001 0.00 0.00% |
Instadose Pharma vs Argenx NV Correlation
At present, Instadose Pharma's Return On Equity is projected to slightly grow based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 623.27, whereas Net Tangible Assets are projected to grow to (138.8 K).Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Instadose Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Instadose Pharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Instadose Pharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Instadose and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Instadose Pharma Corp does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Instadose Stock performing well and Instadose Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Instadose Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| COR | 1.18 | (0.02) | 0.00 | (0.06) | 0.00 | 2.01 | 10.81 | |||
| REGN | 1.54 | 0.16 | 0.09 | 0.40 | 1.46 | 3.40 | 8.86 | |||
| IDXX | 1.27 | (0.21) | 0.00 | (0.15) | 0.00 | 3.61 | 10.16 | |||
| HLN | 0.98 | 0.16 | 0.10 | 0.80 | 1.09 | 2.76 | 5.40 | |||
| CI | 1.17 | 0.05 | 0.03 | 0.12 | 1.22 | 2.64 | 7.36 | |||
| ELV | 1.55 | 0.04 | 0.02 | 0.08 | 2.81 | 3.20 | 19.95 | |||
| BDX | 1.18 | 0.31 | 0.24 | (2.30) | 0.70 | 3.22 | 7.13 | |||
| ELAN | 1.51 | 0.15 | 0.08 | 0.17 | 1.72 | 3.66 | 10.56 | |||
| ARGX | 1.18 | (0.06) | 0.00 | 0.35 | 0.00 | 2.38 | 7.34 |
Cross Equities Net Income Analysis
Compare Instadose Pharma Corp and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COR | (207.7 M) | 719 M | 433.7 M | 276.5 M | (134.9 M) | 1.4 B | 414.5 M | 1.7 B | 855.4 M | (3.4 B) | 1.5 B | 1.7 B | 1.7 B | 1.5 B | 1.6 B | 1.8 B | 1.9 B |
| REGN | (3.3 M) | (221.8 M) | 750.3 M | 424.4 M | 348.1 M | 636.1 M | 895.5 M | 1.2 B | 2.4 B | 2.1 B | 3.5 B | 8.1 B | 4.3 B | 4 B | 4.4 B | 4.5 B | 4.7 B |
| IDXX | 3.2 M | 161.8 M | 178.3 M | 187.8 M | 181.9 M | 192.1 M | 222 M | 263.1 M | 377 M | 427.7 M | 581.8 M | 744.8 M | 679.1 M | 845 M | 887.9 M | 1.1 B | 1.1 B |
| HLN | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 655 M | 1.1 B | 1.4 B | 1.1 B | 1 B | 1.4 B | 1.7 B | 1.2 B |
| CI | (854.6 M) | 1.3 B | 1.6 B | 1.5 B | 2.1 B | 2.1 B | 1.9 B | 2.2 B | 2.6 B | 5.1 B | 8.5 B | 5.4 B | 6.7 B | 5.2 B | 3.4 B | 6 B | 6.3 B |
| ELV | 172.4 M | 2.6 B | 2.7 B | 2.7 B | 2.6 B | 2.6 B | 2.5 B | 3.8 B | 3.8 B | 4.8 B | 4.6 B | 6.1 B | 5.9 B | 6 B | 6 B | 5.7 B | 3.3 B |
| BDX | 88 M | 1.2 B | 1.3 B | 1.2 B | 695 M | 976 M | 1.1 B | 311 M | 1.2 B | 874 M | 2.1 B | 1.8 B | 1.5 B | 1.7 B | 1.7 B | 1.9 B | 2 B |
| ELAN | (210.8 M) | (210.8 M) | (210.8 M) | (210.8 M) | (210.8 M) | (210.8 M) | (47.9 M) | (310.7 M) | 86.5 M | 67.9 M | (560.1 M) | (483 M) | (78 M) | (1.2 B) | 338 M | 304.2 M | 319.4 M |
| ARGX | (4.5 M) | (4.5 M) | (12.8 M) | (8.5 M) | (12.5 M) | (16.7 M) | (22.5 M) | (33.7 M) | (76.2 M) | (181.2 M) | (608.5 M) | (407.6 M) | (709.6 M) | (295.1 M) | 833 M | 749.7 M | 787.2 M |
Instadose Pharma Corp and related stocks such as Cencora, Regeneron Pharmaceuticals, and IDEXX Laboratories Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Instadose Pharma Corp financial statement analysis. It represents the amount of money remaining after all of Instadose Pharma Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Instadose Pharma Competitive Analysis
The better you understand Instadose Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Instadose Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Instadose Pharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Instadose Pharma Competition Performance Charts
Five steps to successful analysis of Instadose Pharma Competition
Instadose Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Instadose Pharma Corp in relation to its competition. Instadose Pharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Instadose Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Instadose Pharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Instadose Pharma Corp, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Instadose Pharma position
In addition to having Instadose Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Crypto And Gold Thematic Idea Now
Crypto And Gold
Assets that cancel away each other volatility by providing diversification into gold investment combined with digital assets. The Crypto And Gold theme has 54 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Crypto And Gold Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Instadose Pharma Correlation with its peers. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Pharmaceuticals sector continue expanding? Could Instadose diversify its offerings? Factors like these will boost the valuation of Instadose Pharma. Market participants price Instadose higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Instadose Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Instadose Pharma Corp using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Instadose Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Instadose Pharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Instadose Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instadose Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Instadose Pharma's market price signifies the transaction level at which participants voluntarily complete trades.